Pfizer Would Explore Where No Other Firm Has Gone Before With Lipitor Switch
Source: The Tan Sheet
Jim Dibiasi, co-founder of NDA consultancy 3D Communications, says consumers should be trusted to access information other than what is printed on product labels before deciding whether to use OTC drugs indicated for conditions that so far are not targeted in the nonprescription space.
“If a supplemental label is needed, add it. The bottom line is that FDA should be less restrictive in the Rx-to-OTC switch approval process,” DiBiasi said in an email.
For the full article, click HERE.